Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

299

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
DRUG

Ritalin LA (methylphenidate hydrochloride extended release)

Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.

Trial Locations (48)

1180

Novartis Investigative Site, Uccle

2800

Novartis Investigative Site, Mechelen

3010

Novartis Investigative Site, Kessel-Lo

3550

Novartis Investigative Site, Heusden-Zolder

8000

Novartis Investigative Site, Århus C

8310

Novartis Investigative Site, Bruges

10629

Novartis Investigative Site, Berlin

12203

Novartis Investigative Site, Berlin

19149

Novartis Investigative Site, Philadelphia

20259

Novartis Investigative Site, Hamburg

26655

Novartis Investigative Site, Westerstede/Oldenburg

32806

Novartis Investigative Site, Orlando

33407

Novartis Investigative Site, West Plam Beach

34208

Novartis Investigative Site, Bradenton

38444

Novartis Investigative Site, Wolfsburg

42301

Novartis Investigative Site, Owensboro

43210

Novartis Investigative Site, Columbus

55131

Novartis Investigative Site, Mainz

57076

Novartis Investigative Site, Siegen

58103

Novartis Investigative Site, Fargo

60048

Novartis Investigative Site, Libertyville

65549

Novartis Investigative Site, Limburg

66421

Novartis Investigative Site, Homburg

68159

Novartis Investigative Site, Mannheim

71636

Novartis Investigative Site, Ludwigsburg

72205

Novartis Investigative Site, Little Rock

76829

Novartis Investigative Site, Landau

77007

Novartis Investigative Site, Houston

79104

Novartis Investigative Site, Freiburg im Breisgau

79106

Novartis Investigative Site, Freiburg im Breisgau

80333

Novartis Investigative Site, München

89081

Novartis Investigative Site, Ulm

89119

Novartis Investigative Site, Las Vegas

89128

Novartis Investigative Site, Las Vegas

90210

Novartis Investigative Site, Beverly Hills

90419

Novartis Investigative Site, Nuremberg

96047

Novartis Investigative Site, Bamberg

97070

Novartis Investigative Site, Würzburg

98004

Novartis Investigative Site, Bellevue

98104

Novartis Investigative Site, Seattle

91978-1522

Novartis Investigative Site, Spring Valley

0000

Novartis Investigative Site, Santa Fe de Antioquia

Unknown

Novartis Investigative Site, Antioquia

06618

Novartis Investigative Site, Naumburg

01129

Novartis Investigative Site, Dresden

04157

Novartis Investigative Site, Leipzig

972 35

Novartis Investigative Site, Luleå

211 53

Novartis Investigative Site, Malmo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY